A detailed history of Virtus ETF Advisers LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 39,069 shares of IOVA stock, worth $334,039. This represents 0.18% of its overall portfolio holdings.

Number of Shares
39,069
Previous 39,069 -0.0%
Holding current value
$334,039
Previous $313,000 16.93%
% of portfolio
0.18%
Previous 0.16%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $216,532 - $394,936
27,832 Added 247.68%
39,069 $313,000
Q1 2024

May 15, 2024

SELL
$7.59 - $17.47 $5,851 - $13,469
-771 Reduced 6.42%
11,237 $166,000
Q4 2023

Feb 15, 2024

BUY
$3.3 - $8.89 $1,989 - $5,360
603 Added 5.29%
12,008 $97,000
Q3 2023

Nov 07, 2023

SELL
$4.44 - $8.79 $5,048 - $9,994
-1,137 Reduced 9.07%
11,405 $51,000
Q2 2023

Aug 14, 2023

SELL
$5.36 - $9.06 $13,223 - $22,351
-2,467 Reduced 16.44%
12,542 $88,000
Q1 2023

May 15, 2023

SELL
$5.53 - $8.22 $31,924 - $47,454
-5,773 Reduced 27.78%
15,009 $91,000
Q4 2022

Feb 14, 2023

BUY
$5.62 - $10.0 $40,818 - $72,630
7,263 Added 53.72%
20,782 $132,000
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $991 - $1,363
104 Added 0.78%
13,519 $130,000
Q2 2022

Aug 12, 2022

BUY
$6.38 - $18.33 $30,317 - $87,104
4,752 Added 54.85%
13,415 $148,000
Q1 2022

May 16, 2022

SELL
$12.38 - $19.1 $6,425 - $9,912
-519 Reduced 5.65%
8,663 $144,000
Q4 2021

Feb 14, 2022

BUY
$16.55 - $27.63 $4,650 - $7,764
281 Added 3.16%
9,182 $175,000
Q3 2021

Nov 15, 2021

SELL
$20.35 - $26.63 $9,564 - $12,516
-470 Reduced 5.02%
8,901 $219,000
Q2 2021

Aug 10, 2021

BUY
$16.33 - $33.07 $55,521 - $112,438
3,400 Added 56.94%
9,371 $244,000
Q1 2021

May 17, 2021

BUY
$28.67 - $52.59 $2,895 - $5,311
101 Added 1.72%
5,971 $189,000
Q4 2020

Feb 12, 2021

SELL
$28.04 - $50.26 $128,423 - $230,190
-4,580 Reduced 43.83%
5,870 $272,000
Q3 2020

Nov 13, 2020

SELL
$27.75 - $36.3 $39,377 - $51,509
-1,419 Reduced 11.96%
10,450 $344,000
Q2 2020

Aug 05, 2020

SELL
$27.21 - $41.0 $51,209 - $77,162
-1,882 Reduced 13.69%
11,869 $326,000
Q1 2020

May 14, 2020

SELL
$19.54 - $38.85 $39,334 - $78,205
-2,013 Reduced 12.77%
13,751 $412,000
Q4 2019

Feb 13, 2020

BUY
$17.95 - $29.41 $45,575 - $74,671
2,539 Added 19.2%
15,764 $436,000
Q3 2019

Nov 12, 2019

SELL
$17.99 - $26.0 $13,258 - $19,162
-737 Reduced 5.28%
13,225 $241,000
Q2 2019

Aug 13, 2019

BUY
$9.78 - $24.52 $136,548 - $342,348
13,962 New
13,962 $342,000
Q1 2019

May 14, 2019

SELL
$8.41 - $11.26 $252,947 - $338,667
-30,077 Closed
0 $0
Q4 2018

Feb 05, 2019

SELL
$7.51 - $11.93 $45,382 - $72,092
-6,043 Reduced 16.73%
30,077 $266,000
Q3 2018

Nov 14, 2018

SELL
$11.25 - $17.7 $290,598 - $457,208
-25,831 Reduced 41.7%
36,120 $406,000
Q2 2018

Aug 10, 2018

SELL
$12.45 - $16.95 $360,738 - $491,126
-28,975 Reduced 31.87%
61,951 $793,000
Q1 2018

May 14, 2018

BUY
$8.1 - $19.5 $410,402 - $988,006
50,667 Added 125.85%
90,926 $1.54 Million
Q4 2017

Feb 14, 2018

SELL
$6.65 - $9.25 $94,855 - $131,942
-14,264 Reduced 26.16%
40,259 $322,000
Q3 2017

Nov 14, 2017

BUY
$4.45 - $8.55 $22,192 - $42,638
4,987 Added 10.07%
54,523 $423,000
Q2 2017

Aug 14, 2017

BUY
N/A
49,536
49,536 $364,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.